Acuta Capital Partners, LLC Hille Vax, Inc. Transaction History

Acuta Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$14.15 - $19.75 $1.05 Million - $1.46 Million	-73,991 Reduced 22.79%	250,609 $4.17 Million
Q4 2023 Feb 14, 2024	BUY	$10.35 - $17.11 $561,808 - $928,747	54,281 Added 20.08%	324,600 $5.21 Million
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $2.4 Million - $3.46 Million	207,241 Added 328.55%	270,319 $3.64 Million
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.76 $729,433 - $1.06 Million	56,414 Added 846.55%	63,078 $1.08 Million
Q1 2023 May 15, 2023	BUY	$14.73 - $18.18 $98,160 - $121,151	6,664 New	6,664 $110,000

35.5M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $62.5M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.